News

Oral fludarabine is currently marketed by Schering AG in the EU and Canada under the trade name, Fludara, for the treatment of relapsed B-cell chronic lymphocytic leukemia (CLL).

Under the terms of the multi-year agreement, Genentech makes an upfront payment to CGI of $25 million. Genentech obtains an exclusive license to develop and market small molecules

The study will evaluate the efficacy and safety of Zevalin in patients with diffuse large-B-cell lymphoma (DLBCL) the most common type of aggressive non-Hodgkin's lymphoma. The primary endpoint

Lodotra is a new, modified-release tablet that has been developed in partnership with Nitec Pharma to optimize the efficacy of orally administered low-dose prednisone in rheumatoid arthritis. Lodotra

Under the expanded agreement, UCB has made an upfront payment and will make milestone payments to Jazz Pharmaceuticals. If the product is approved, UCB obtains the right to

The study compared these results to patients taking an alternative treatment for MS called interferon beta. Only 30% of patients taking interferon beta remained on the treatment. The

Ozarelix is used in the treatment of Benign Prostatic Hypertrophy (BPH), an enlargement of the prostate gland. The trial was conducted in Europe in collaboration with Spectrum’s partner

This phase I dose escalation study is intended to define the dose limiting toxicities and maximum tolerated dose of ADH-1 in three separate studies with the chemotherapy treatments

Peripheral T-cell lymphomas, or PTCLs, are an uncommon group of blood cancers that account for approximately 10% to 15% of all cases of non-Hodgkin’s lymphoma, or about 6,700